Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.

Induction of selective degradation of target proteins by small molecules (protein knockdown) would be useful for biological research and treatment of various diseases. To achieve protein knockdown, we utilized the ubiquitin ligase activity of cellular inhibitor of apoptosis protein 1 (cIAP1), which is activated by methyl bestatin (MeBS, 2). We speculated that formation of an artificial (nonphysiological) complex of cIAP1 and a target protein would be induced by a hybrid molecule consisting of MeBS (2) linked to a ligand of the target protein, and this would lead to cIAP1-mediated ubiquitination and subsequent proteasomal degradation of the target protein. To verify this hypothesis, we focused on cellular retinoic acid-binding proteins (CRABP-I and -II) and designed hybrid molecules (compounds 4) consisting of MeBS (2) coupled via spacers of various lengths to all-trans retinoic acid (ATRA, 3), a ligand of CRABPs. Compounds 4 induced selective loss of CRABP-I and -II proteins in cells. We confirmed that 4b induced formation of a complex of cIAP1 and CRABP-II in vitro and induced proteasomal degradation of CRABP-II in cells. When neuroblastoma IMR-32 cells were treated with 4b, the level of CRABP-II was reduced and cell migration was inhibited, suggesting potential value of CRABP-II-targeting therapy for controlling tumor metastasis. Our results indicate that 4b possesses sufficient activity, permeability, and stability in cells to be employed in cellular assays. Hybrid molecules such as 4 should be useful not only as chemical tools for studying the biological/physiological functions of CRABPs but also as candidate therapeutic agents targeting CRABPs.

[1]  Anindita Dutta,et al.  Studies on Multifunctional Effect of All-Trans Retinoic Acid (ATRA) on Matrix Metalloproteinase-2 (MMP-2) and Its Regulatory Molecules in Human Breast Cancer Cells (MCF-7) , 2009, Journal of oncology.

[2]  R. Deshaies,et al.  RING domain E3 ubiquitin ligases. , 2009, Annual review of biochemistry.

[3]  Yan Wang,et al.  Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells. , 2009, Asian journal of andrology.

[4]  A. Weninger,et al.  Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ42 reduces their differentiation potential , 2008, BMC medicine.

[5]  B. Williams,et al.  Regulation of CRABP-II expression by MycN in Wilms tumor. , 2008, Experimental cell research.

[6]  R. Deshaies,et al.  Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer , 2008, Oncogene.

[7]  C. Crews,et al.  Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.

[8]  Y. Hashimoto,et al.  Demonstration of direct binding of cIAP1 degradation-promoting bestatin analogs to BIR3 domain: Synthesis and application of fluorescent bestatin ester analogs. , 2008, Bioorganic & medicinal chemistry letters.

[9]  T. Schug,et al.  Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR , 2008, Proceedings of the National Academy of Sciences.

[10]  T. Tsuruo,et al.  Small Molecules Destabilize cIAP1 by Activating Auto-ubiquitylation* , 2008, Journal of Biological Chemistry.

[11]  H. Swanson,et al.  Development of an Aryl Hydrocarbon Receptor Antagonist Using the Proteolysis-Targeting Chimeric Molecules Approach: A Potential Tool for Chemoprevention , 2008, Molecular Pharmacology.

[12]  V. Haase,et al.  The VHL tumor suppressor and HIF: insights from genetic studies in mice , 2008, Cell Death and Differentiation.

[13]  J. Errey,et al.  From disulfide- to thioether-linked glycoproteins. , 2008, Angewandte Chemie.

[14]  A. Tsimokha,et al.  Role of proteasomes in cellular regulation. , 2008, International review of cell and molecular biology.

[15]  E. Choi,et al.  Targeted Degradation of the Aryl Hydrocarbon Receptor by the PROTAC Approach: A Useful Chemical Genetic Tool , 2007, Chembiochem : a European journal of chemical biology.

[16]  C. Robson,et al.  Analysis of the MDM2 antagonist nutlin‐3 in human prostate cancer cells , 2007, The Prostate.

[17]  T. Schug,et al.  Opposing Effects of Retinoic Acid on Cell Growth Result from Alternate Activation of Two Different Nuclear Receptors , 2007, Cell.

[18]  J. Huibregtse,et al.  Regulation of catalytic activities of HECT ubiquitin ligases. , 2007, Biochemical and biophysical research communications.

[19]  Si-Wouk Kim,et al.  Enhancing effect of indirubin derivatives on 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells. , 2006, Bioorganic & medicinal chemistry.

[20]  S. Hanash,et al.  Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma. , 2006, Cancer research.

[21]  M. Wigler,et al.  Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.

[22]  D. Goeddel,et al.  Posttranscriptional Downregulation of c-IAP2 by the Ubiquitin Protein Ligase c-IAP1 In Vivo , 2005, Molecular and Cellular Biology.

[23]  David L. Vaux,et al.  IAPs, RINGs and ubiquitylation , 2005, Nature Reviews Molecular Cell Biology.

[24]  Kazuhiko Aoyagi,et al.  Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. , 2005, Cancer research.

[25]  B. Williams,et al.  Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia , 2005, Oncogene.

[26]  D. Neal,et al.  Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation , 2005, Nucleic acids research.

[27]  L. Gediya,et al.  Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. , 2004, Journal of medicinal chemistry.

[28]  Amy P N Skubitz,et al.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers. , 2004, The American journal of pathology.

[29]  Michael A. Koldobskiy,et al.  Chemical genetic control of protein levels: selective in vivo targeted degradation. , 2004, Journal of the American Chemical Society.

[30]  S. Samuel,et al.  Adhesion, migration, transcriptional, interferon‐inducible, and other signaling molecules newly implicated in cancer susceptibility and resistance of JB6 cells by cDNA microarray analyses , 2004, Molecular carcinogenesis.

[31]  A. Ransick,et al.  Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation* , 2003, Molecular & Cellular Proteomics.

[32]  Jane Fridlyand,et al.  Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. , 2003, Cancer research.

[33]  Wei-Guo Zhu,et al.  A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. , 2003, Human molecular genetics.

[34]  Masahiko Miura,et al.  Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. , 2002, Cancer research.

[35]  S. Mane,et al.  Insights from gene arrays on the development and growth regulation of uterine leiomyomata. , 2002, Fertility and sterility.

[36]  Christopher J. Schofield,et al.  Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL , 2002, Nature.

[37]  Charles A Powell,et al.  Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. , 2002, The American journal of pathology.

[38]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[39]  A. Budhu,et al.  Direct Channeling of Retinoic Acid between Cellular Retinoic Acid-Binding Protein II and Retinoic Acid Receptor Sensitizes Mammary Carcinoma Cells to Retinoic Acid-Induced Growth Arrest , 2002, Molecular and Cellular Biology.

[40]  F. Redegeld,et al.  Replacement of the Intervening Amino Acid Sequence of a Syk‐Binding Diphosphopeptide by a Nonpeptide Spacer with Preservation of High Affinity , 2002, Chembiochem : a European journal of chemical biology.

[41]  K. Nishikawa,et al.  Augmentation of death ligand‐induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines , 2001, International journal of cancer.

[42]  J. Inazawa,et al.  Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. , 2001, Cancer research.

[43]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Ciechanover,et al.  Ubiquitin‐mediated proteolysis: biological regulation via destruction , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[45]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[46]  R. Deshaies SCF and Cullin/Ring H2-based ubiquitin ligases. , 1999, Annual review of cell and developmental biology.

[47]  D. Crowe,et al.  Transcriptional regulation of retinoic acid responsive genes by cellular retinoic acid binding protein-II modulates RA mediated tumor cell proliferation and invasion. , 1998, Anticancer research.

[48]  John Calvin Reed,et al.  The c‐IAP‐1 and c‐IAP‐2 proteins are direct inhibitors of specific caspases , 1997, The EMBO journal.

[49]  C. Geisen,et al.  High-Level Expression of the Retinoic Acid Receptor β Gene in Normal Cells of the Uterine Cervix Is Regulated by the Retinoic Acid Receptor α and Is Abnormally Down-Regulated in Cervical Carcinoma Cells , 1997 .

[50]  M. Kizaki,et al.  Retinoid resistance in leukemic cells. , 1997, Leukemia & lymphoma.

[51]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[52]  M. Donovan,et al.  The cellular retinoic acid binding proteins , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[53]  T. A. Jones,et al.  Crystal structures of cellular retinoic acid binding proteins I and II in complex with all-trans-retinoic acid and a synthetic retinoid. , 1995, Structure.

[54]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[55]  Y. Kita,et al.  Protecting Group for Carboxyl Function : Mild and Facile Cleavage of 2-Cyanoethyl Ester under Non-hydrolytic Conditions , 1994 .

[56]  J. Voorhees,et al.  Expression, purification, and binding properties of human cellular retinoic acid-binding protein type I and type II. , 1993, Archives of biochemistry and biophysics.

[57]  C. Mioskowski,et al.  Synthesis of New Phospholipids Linked to Steroid‐Hormone Derivatives Designed for Two‐Dimensional Crystallization of Proteins , 1991 .

[58]  James T. Elder,et al.  Molecular cloning of two human cellular retinoic acid-binding proteins (CRABP). Retinoic acid-induced expression of CRABP-II but not CRABP-I in adult human skin in vivo and in skin fibroblasts in vitro. , 1991, The Journal of biological chemistry.

[59]  J. L. Napoli,et al.  Expression of cellular retinoic acid binding protein (CRABP) in Escherichia coli. Characterization and evidence that holo-CRABP is a substrate in retinoic acid metabolism. , 1991, The Journal of biological chemistry.

[60]  S. Iwasaki,et al.  Fluorescent and photoaffinity labeling probes for retinoic acid receptors. , 1991, Biochemical and biophysical research communications.

[61]  G. Siegenthaler,et al.  Ligand specificities of recombinant retinoic acid receptors RAR alpha and RAR beta. , 1990, The Biochemical journal.

[62]  J. Chapman,et al.  Affinity purification of retinoic acid-binding proteins using immobilized 4-(2-hydroxyethoxy)retinoic acid. , 1990, Protein expression and purification.